Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD

Written By Andrew Lee
Read the article

Andrew Lee
Previous

Exclusive: Spot Bio launches with $40M to study mRNA therapy for muscular dystrophy
Next

Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy